Company: TXG
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001770787-25-000018
Chunk: 18

Company: 10x Genomics, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 18
---
 and equity plans;

• overseeing the development, implementation and effectiveness of our practices, policies and strategies relating to human capital management including matters relating to recruiting, selection, talent development, progression and retention, culture and human health and safety practices;

• overseeing our compliance with, the company's change in control severance policy, death and disability policy and equity award delegation policy;

• reviewing the risks that may arise from our compensation programs; and

• establishing and reviewing general policies relating to compensation and benefits of our employees.

#### Mergers and Acquisitions Committee
The members of our mergers and acquisitions committee are Mr. Kosaraju and Drs. Suliman and Stuelpnagel, with Mr. Kosaraju serving as the chairperson. Our mergers and acquisitions committee did not meet in 2024. The chairperson and members of the mergers and acquisition committee were not compensated for their service on the committee in 2024. Our mergers and acquisitions committee assists the board of directors in reviewing, assessing and, in some circumstances, approving potential mergers, acquisitions, divestitures and other similar strategic transactions and meets on an ad hoc basis.

#### Nominating and Corporate Governance Committee
The members of our nominating and corporate governance committee during 2024 were Drs. Suliman (chair) and Mammen until Dr. Mammen's resignation in October 2024. Upon the resignation of Dr. Mammen effective as of October 24, 2024, our nominating and corporate governance committee consisted solely of Dr. Suliman until our Board reconstituted the nominating and corporate

#### 10X GENOMICS, INC.152025 PROXY STATEMENT
governance committee, effective as of December 19, 2024, to consist of Dr. Suliman and Mr. Mateo, with Dr. Suliman continuing to serve as chairperson.

During 2024, our nominating and corporate governance committee held one meeting. Our nominating and corporate governance committee is responsible for, among other things:

• identifying, evaluating and recommending candidates for membership on our board of directors, including the consideration of nominees submitted by stockholders, and to each of the board’s committees;

• reviewing and evaluating the adequacy of our Corporate Governance Guidelines;

• overseeing the process of evaluating the performance of our board of directors; and

• assisting our board of directors on corporate governance matters.

It is the policy of the nominating and corporate governance committee of our board of directors to consider